-
Discussion on the "negative value" of 24-hour urine protein test
Time of Update: 2021-11-11
figure 1Picture 1 Picture 1figure 2Picture 2 Picture 2case analysisCase study case studyThe 24-hour urine protein detection equipment is a Beckman (AU5821) automatic biochemical analyzer.
Studies have shown that 24-hour urine specimens have no effect on their urine protein test results after they are placed at room temperature (25°C).
-
Case report: skin rash finally diagnosed with leukemia-N Engl J Med
Time of Update: 2021-11-11
Symmetrically distributed erythema and purple patches on the back of the hands and elbowsLaboratory examination showed that the white blood cell count was 16,000 per cubic millimeter (reference range, 4200 to 10,200), and the platelet count was 70,000 per cubic millimeter (reference range, 145,00 to 348,000) .
-
Nat Nanotech: Chinese scholars have developed a highly efficient bionic delivery vehicle loaded with arsenic, which can significantly inhibit a variety of leukemias
Time of Update: 2021-11-11
The State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, based on the natural components of ferritin particles (Fn) in the body and the approved drug arsenic trioxide (ATO), proposed a new strategy for biomimetic delivery, and cooperated with Peking University and Zhujiang Hospital.
-
Science publications reveal the "new identity" of red blood cells: not only oxygen "porters", but also human immune "sentinels"
Time of Update: 2021-11-11
The combination of CpG-DNA of bacteria, plasmodium and mitochondria accelerates red blood cell phagocytosis and innate immune activation, promotes the secretion of inflammatory cytokines, and the maturation and proliferation of immune cells, thereby acting as an immune sentinel under pathological conditions.
-
Closely related to acupuncture points! A team of Chinese scientists discovered for the first time that there is a "tissue fluid circulation network" in the human body
Time of Update: 2021-11-11
On October 23 , Beijing Hospital announced the original scientific discovery of Professor Li Hongyi’s team: the anatomical structure of the “ human tissue fluid circulation network ” was discovered fo
-
PNH Famous Doctors Lecture Session 6 Professor Guangsheng He: PNH Treatment-Transplantation
Time of Update: 2021-11-05
In this issue of "PNH Famous Doctors Lecture", Yimaitong invited Professor He Guangsheng from Jiangsu Provincial People's Hospital to share on the status and application of allogeneic hematopoietic stem cell transplantation in PNH!
The risk of allogeneic hematopoietic stem cell transplantation for PNH patients is related to blood transfusion and iron overload.
-
Express targeting RNA-modified protein to treat leukemia, Ipsen reached over 400 million US dollars in cooperation
Time of Update: 2021-11-05
▎Editor of WuXi AppTec content team On October 18, 2021, Ipsen and Accent Therapeutics announced that they have reached an exclusive global cooperation agreement to advance the research, development, manufacturing and commercialization of drugs targeting the RNA-modified protein METL3 .
-
Professor Zhang Xi: Maintenance Therapy after AML/MDS Hematopoietic Stem Cell Transplantation The 16th National Leukemia and Lymphoma Conference
Time of Update: 2021-11-05
At this conference, Professor Zhang Xi from the Second Affiliated Hospital of the Army Military Medical University conducted the topic of "Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Maintenance Treatment after Hematopoietic Stem Cell Transplantation (Epigenetic Regulation)" In the report, Yimaitong organizes the main contents as follows .
-
An article to understand new therapies for relapsed/refractory mantle cell lymphoma
Time of Update: 2021-11-05
The overall response rate (ORR) of these drugs for single-agent R/R MCL treatment is 67%-84%, and the median progression-free survival (PFS) is 13-22 months.
-
Prof. Sun Zimin: The 16th National Leukemia and Lymphoma Academic Conference of the Chinese Medical Association was brilliant, and the future of leukemia diagnosis and treatment can be expected!
Time of Update: 2021-11-05
October 8-10, 2021, hosted by the Chinese Medical Association, Chinese Medical Association Hematology Branch, Chinese Medical Association Hematology Branch Leukemia and Lymphoma Group, Chinese Academ
-
Gene mutation-based treatment decision tools can identify elderly AML patients who benefit from intensive treatment
Time of Update: 2021-11-05
The researchers combined the mutations of 7 genes (NPM1, FLT3-ITD, DNMT3A, ASXL1, NRAS, KRAS, TP53) and cytogenetic risk stratification to develop an ALFA treatment decision tool for elderly AML patients.
-
Professor Qian Jiang: Current status and prospects of CML treatment The 16th National Leukemia and Lymphoma Conference
Time of Update: 2021-11-05
Yimaitong: At present, relevant research is exploring how to make CML patients still obtain long-term disease remission after stopping the TKI.
Considering that most CML patients can still control the disease well under the condition of long-term medication, it is not recommended that all CML patients pursue treatment-free remission (TFR) after drug withdrawal .
-
Professor Wei Hui talks about the progress and prospects of treatment of acute myeloid leukemia
Time of Update: 2021-11-05
Professor Wei Hui currently, targeted drugs have become an important treatment option for AML patients.
Secondly, for elderly patients and relapsed and refractory patients, chemotherapy combined with targeted drug therapy has become the recommended guideline for the treatment of AML.
-
The 2nd China Blood and Transplant Forum Announces Significantly | Basiliximab has a significant effect in the treatment of SR-aGVHD
Time of Update: 2021-11-05
Acute graft versus host disease (aGVHD) is a unique and common complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), which seriously affects the prognosis of the recipient [
-
Professor Zhou Jianfeng: Current status, challenges and prospects of CAR-T cell therapy for hematological tumors The 16th National Leukemia and Lymphoma Academic Conference
Time of Update: 2021-11-05
In conclusion, Professor Zhou concluded that CAR-T cell therapy has brought new hope for patients to cure and is changing the pattern of hematological tumor treatment.
-
The "sniper" of precision medicine: CLL/WM genetic testing
Time of Update: 2021-11-05
Professor Li Jianyong: For CLL patients with TP53 gene abnormalities, no mutations in IGHV gene, and complex chromosomal karyotype abnormalities, a chemo-free strategy based on new drugs represented by Ibritinib is the first choice .
Professor Li Jianyong: Precision medicine plays an extremely important role in clinical diagnosis, prognostic evaluation, treatment selection, and further drug development .
-
Professor Liu Yao issued the first batch of prescriptions for CAR-T in Chongqing, writing a new chapter in the treatment of hematological tumor patients
Time of Update: 2021-11-05
Under the premise of meeting the indications, the following factors should be considered in screening patients: First, try to control the patient’s condition and avoid CAR-T treatment during the advanced stage of the disease; second, the patient’s physical status must meet relevant standards and be able to Withstand the collection and cleansing before CAR-T cell infusion .
-
Professor Luo Xuequn: The genetic abnormalities of acute myeloid leukemia and their significance
Time of Update: 2021-11-04
Foreword September 25-26, 2021, co-sponsored by the Pediatric Oncology Committee of the Guangdong Anti-Cancer Association and the Pediatric Oncology Committee of the Chinese Anti-Cancer Association,
-
One article counts the treatment of low-risk myelodysplastic syndromes
Time of Update: 2021-11-04
For patients with del(5q) MDS, lenalidomide is the preferred treatment method, with a higher incidence of RBC transfusion independence (TI) .
Related research is exploring the efficacy of this new type of drug (compared with or combined with ESA) in the early treatment of LR-MDS patients .
-
Chinese experience goes global——Professor Zhao Weilai shared valuable experience of CAR-T treatment at the APBMT conference
Time of Update: 2021-11-04
Professor Zhao Weilai shared the treatment and management of two Chinese DLBCL patients receiving CAR-T cell therapy.
Another Chinese patient shared by Professor Zhao Weilai is a 76-year-old female diagnosed with Non-GCB DLBCL, Ann Arbor stage IIIA, IPI score of 2, and a previous history of Sjogren’s syndrome .
